 <h1>Talzenna Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>talazoparib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about talazoparib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Talzenna.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to talazoparib: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, talazoparib (the active ingredient contained in Talzenna) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking talazoparib:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>hoarseness</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swelling or inflammation of the mouth</li>
<li>swollen glands</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of talazoparib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Belching</li>
<li>change or loss of taste</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>headache</li>
<li>heartburn</li>
<li>indigestion</li>
<li>nausea</li>
<li>stomach discomfort, upset, or pain</li>
<li>thinning or loss of hair</li>
<li>vomiting</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to talazoparib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (e.g., anemia, hematocrit decreased, hemoglobin decreased, red blood cell count decreased) (53%), neutropenia (e.g., febrile neutropenia, neutropenia and neutrophil count decreased) (35%), thrombocytopenia (e.g., thrombocytopenia, platelet count decreased) (27%), leukopenia (17%) </p>
<p><b>Common</b> (1% to 10%): Lymphopenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Glucose increased (54%), calcium decreased (28%), decreased appetite (21%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): AST increased (37%), ALP increased (36%), ALT increased (33%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Myelodysplastic syndrome, acute myeloid leukemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (62%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (33%), dizziness (17%), dysgeusia (10%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (25%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (49%), vomiting (25%), diarrhea (22%), abdominal pain (19%), dyspepsia (10%)</p>
<p><b>Common</b> (1% to 10%): Stomatitis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of drug is Talzenna?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Talzenna (talazoparib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: PARP inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Talzenna &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to talazoparib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (e.g., anemia, hematocrit decreased, hemoglobin decreased, red blood cell count decreased) (53%), neutropenia (e.g., febrile neutropenia, neutropenia and neutrophil count decreased) (35%), thrombocytopenia (e.g., thrombocytopenia, platelet count decreased) (27%), leukopenia (17%) </p><p><b>Common</b> (1% to 10%): Lymphopenia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Glucose increased (54%), calcium decreased (28%), decreased appetite (21%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): AST increased (37%), ALP increased (36%), ALT increased (33%)<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Myelodysplastic syndrome, acute myeloid leukemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue/asthenia (62%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (33%), dizziness (17%), dysgeusia (10%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (25%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (49%), vomiting (25%), diarrhea (22%), abdominal pain (19%), dyspepsia (10%)</p><p><b>Common</b> (1% to 10%): Stomatitis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Talzenna (talazoparib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of drug is Talzenna?</li>
</ul><h2>More about Talzenna (talazoparib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: PARP inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Talzenna &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Breast Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>